Sichuan Kelun Pharmaceutical (002422.SZ)

Overall impact
C (43)

Commentary

Sichuan Kelun Pharmaceutical is an average overall performer. With a 'C' rating of 43.1 for overall impact (28th percentile compared to all companies), Sichuan Kelun Pharmaceutical ranks 147th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 143 others, and ahead of Curaleaf, Arcutis Biotherapeutics, Sun Pharmaceutical Industries and 4 others. On top material causes for Sichuan Kelun Pharmaceutical's industry (Pharmaceuticals), Sichuan Kelun Pharmaceutical performs well in Disease Eradication (95.9 score) and performs poorly in Reduced Green House Gas Emissions (0.0 score), Sustainable Use of Natural Resources (24.3), Humane Treatment of Animals (14.6) and 7 other causes where it received a 'D' or 'F' score.
Impact
Cause 002422.SZ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1996
Employees
20,127
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
China
Share classes
002422.SZ
Description
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers infusion products; oral medication and other dosage form; plastic ampoule and powder liquid dual chamber infusion bag; medical devices, such as infusion set, injection syringes, detained needles, nebulizer, and blood sampling; and over-the-counter products. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Material causes
Ethos considers the following causes material for Sichuan Kelun Pharmaceutical, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.